Jefferies says Regeneron's Dupixent drug could drive shares 15% higher

Regeneron's Dupixent drug could serve as the next big catalyst for shares of the pharmaceutical company, according to Jefferies.  

Related Keywords

Regeneron Dupixent ,Centers For Disease ,Analyst Akash ,Disease Control ,Wall Street ,Investment Strategy ,Stock Markets ,Regeneron Pharmaceuticals Inc ,Business News ,